Objective: Placement in baboons of a distal femoral arteriovenous fistula increases shear stress through aortoiliac polytetrafluoroethylene (PTFE) grafts and induces regression of a preformed neointima. Atrophy of the neointima might be controlled by shear stress-induced genes, including the bone morphogenetic proteins (BMPs). We have investigated the expression and function of BMPs 2, 4, and 5 in the graft neointima and in cultured baboon smooth muscle cells (SMCs). Methods: Baboons received bilateral aortoiliac PTFE grafts and 8 weeks later, a unilateral femoral arteriovenous fistula. Results: Quantitative polymerase chain reaction showed that high shear stress increased BMP2, 4, and 5 messenger RNA (mRNA) in graft intima between 1 and 7 days, while noggin (a BMP inhibitor) mRNA was decreased. BMP4 most potently (60% inhibition) inhibited platelet-derived growth factor-stimulated SMC proliferation compared with BMP2 and BMP5 (31% and 26%, respectively). BMP4 also increased SMC death by 190% ؎ 10%. Noggin reversed the antiproliferative and proapoptotic effects of BMP4. Clinical Relevance: Pharmacologic therapy to prevent luminal stenosis or restenosis after vascular reconstruction is directed at inhibiting intimal hyperplasia and smooth muscle cell growth. An alternative approach might be to induce intimal atrophy after luminal narrowing has developed. This approach would be particularly useful for treating stenosis in stented vessels or synthetic bypass grafts because intimal hyperplasia is the only mechanism for luminal narrowing. Furthermore, it would permit the physician to treat the population of patients (about 30%) who actually develop a problem with stenosis or restenosis. We have previously provided proof of principle that an established neointima can be induced to atrophy in baboon polytetrafluoroethylene grafts, but not in normal artery, by simply switching from normal to high blood flow and shear stress. In this study, we provide evidence that members of the bone morphogenetic protein family may play a role in this neointimal atrophy.
Exuberant growth of smooth muscle cells (SMCs) is a characteristic of vascular diseases such as pulmonary hypertension, in-stent restenosis, transplant atherosclerosis, and vein graft failure. 1 To date, the pharmacologic strategies employed for these diseases have been aimed at preventing neointimal hyperplasia, which is the primary mechanism of stent and graft stenosis. 2 However, since less than one third of all stents and grafts fail because of intimal hyperplasia, an alternative strategy is to develop therapies that reverse wall thickening in only those patients with hyperplasia.
Proof of principle comes from two studies from our laboratory that used a polytetrafluoroethylene (PTFE) aortoiliac graft model in baboons. In this model, bilateral, unwrapped 60 m internodal distance PTFE grafts are placed into the aortoiliac position. Unlike wrapped 30-m internodal distance PTFE grafts used clinically, these grafts uniformly heal by the ingrowth of capillaries through the interstices of the PTFE graft. Complete endothelialization is achieved by 2 weeks, and maximal, even neointimal thickening is completed by 2 months. [3] [4] [5] Atrophy of this established neointima occurs when either blocking antibodies to platelet-derived growth factor receptors (PDGF)-␣ and -␤ are administered 6 or when blood flow and shear stress are increased by the creation of a distal femoral arteriovenous fistula. 5 The loss of intima is associated with decreased proliferation and increased apoptosis of neointimal SMCs as well as loss of matrix. [7] [8] [9] These results are consistent with the association of increased blood flow and shear stress with decreased intimal thickening in atherosclerotic arteries and vein grafts and injured vessels. 5 Of greater interest with regards to the regression of an established neointima are several similarities of this PTFE model to arteries after stent-angioplasty that undergo spon-taneous intimal regression at late times. 10, 11 Both PTFE grafts and stented arteries are not distensible, have a proteoglycan rich region near the endothelium with less near the inflammatory foreign material, 9, 12 and exhibit increased apoptosis near the foreign material and increased cell proliferation near the endothelium. 8, 12, 13 In the PTFE graft neointima undergoing regression in response to high flow, there is a loss of proteoglycans and a relative increase in collagen, 9 similar to what is observed in stented arteries undergoing spontaneous intimal regression at late times. 14, 15 The PTFE graft thus models interesting aspects of clinically observed pathology.
In this report, we describe our investigation of changes in graft neointimal gene expression in response to high shear stress. Observing that several members of the bone morphogenetic protein (BMP) family were upregulated by elevated shear stress, we focused our investigation on the expression of several members of the BMP family and noggin (a BMP antagonist) in the graft neointima and their effects on cultured baboon SMCs.
METHODS
Complete methods and results, including microarray analysis, are presented as an online Appendix.
Baboon model. Male baboons received bilateral aortoiliac PTFE bypass grafts. After 2 months, unilateral femoral arteriovenous fistulas were constructed as described 7, 8 to increase blood flow and shear stress in the upstream ipsilateral graft and iliac artery. Animals were euthanized at days 1, 4, and 7 (5 each day, 15 total) by using intravenous sodium pentobarbital (160 mg/kg). All procedures were performed in accordance with the guidelines of the University of Washington Institutional Animal Care and Use Committee.
Taqman reverse transcriptase polymerase chain reaction. Total RNA for microarray and Taqman analysis was prepared from the frozen neointima of the graft by using Solution D/phenol/chloroform/isopropanol. 16 RNA quantity and quality was characterized spectrophotometrically by using OD 260/280 (1.96 Ϯ 0.06), by agarose gel electrophoresis, and analysis of the sample on the Agilent 2100 Bioanalyzer (Palo Alto, Calif). Five micrograms of graft intima total RNA from individual animals was combined to form six pools for each time point and blood flow combination; average yield of total RNA from individual grafts was 11 Ϯ 6 g. The rationale for pooling stems from the fact that these animals were used for microarray analysis of the effects of high blood flow on intimal gene expression (see online Appendix). We did not have enough total RNA from some individual animals, so forming pools of the intimal samples taken at 1, 4, and 7 days allowed us to screen about 32,000 genes with four replicates.
Taqman reverse transcriptase-polymerase chain reaction (RT-PCR) of BMP4 and noggin was performed by using the RNA pools with the GeneAmp 5700 sequence detection system (Applied Biosystems, Foster City, Calif). Primers and probes were designed by using Primer Express 2.0 (Applied Biosystems) to cross multiple exons of BMP4 (forward primer 5=-ACCACGAAGAACATCTGGAGAAC-3=, reverse primer 5=-TGCTGAGGTTAAAGAGGAAACGA-3=, probe 5=-6[6-carboxy-fluorescein]-TCCCAGGGACCAGTGAAAACTC-TGCTT-[6-carboxy-tetramethlyl-rhodamine]-3'), and noggin (forward 5=-CCTGGTGGACCTCATCGAA-3=, reverse 5=-CAGCGTCTCGTTCAGATCCTT-3=, probe 5=-6[6-carboxy-fluorescein]-ACCCAGACCCTATCTTTGAC-CCCAAG-GA-[6-carboxy-tetramethlylrhodamine]-3'), and were synthesized by Applied Biosystems. The cycling conditions were 2 minutes at 50°C, 10 minutes at 95°C, followed by 40 cycles of 15 seconds at 95°C, and 1 minute at 60°for combined annealing and extension.
Standard curves of dilutions of plasmids containing BMP4 or noggin (I.M.A.G.E. clone 4399276 and 4727725, Research Genetics) were used to calculate the messenger RNA (mRNA) copy number. Ribosomal RNA control reagents (Applied Biosystems) were used as an internal control, and the calculated amount of mRNA was normalized by the amount of 18S present.
In a separate series of assays on the same RNA pools, quantitation of BMPs 2, 4, and 5 was done using Applied Biosystems predesigned Taqman primer and probe sets (PDARs, see ABI P/N 4333458_a.pdf for the complete protocol). We used Stratagene Universal Target total RNA. We synthesized first strand complimentary DNA (cDNA) by using random primers and the Applied Biosystems High Capacity cDNA Archive Kit (P/N 4322171). Two experiments with duplicate PCR reactions, which used 10-ng equivalents of total RNA, were run on the ABI 7900 machine with the standard cycling protocol and increasing the number of cycles to 44. ␤-Glucuronidase (GUSB) and TATA binding protein (TBP) were used as the internal reference in all of the samples and calibrator. The deltadelta Ct method was used to calculate ratios of each gene in each sample against the calibrator RNA (see ABI P/N 4333458_a.pdf for the complete protocol). Both references gave similar results, and we present the combined average of the GUSB data.
Morphometry and immunohistochemistry. Formalin-fixed, paraffin-embedded, sections of tissue obtained from the middle of the PTFE graft were stained with hematoxylin and eosin, and the neointimal area was determined by computer-assisted morphometry. Neointimal cell proliferation and death indices were determined by anti-bromodeoxyuridine staining and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling of fragmented DNA (TUNEL), as previously described. 8 For immunohistochemical staining, tissue sections were blocked for 1 hour at 37°C with 20% horse serum and 5% albumin, and then incubated overnight at 4°C with goat antibodies to human BMPR-IA, BMPR-IB, and BMPR-II (Santa Cruz Biotechnology Inc, Santa Cruz, Calif). Sections were then incubated with horse biotinylated secondary antibodies (Vector Labs, Burlingame, Calif) at room temperature for 30 minutes, followed by avidin-biotin-peroxidase (Elite ABC kit; Vector Labs). Normal goat immunoglobulin G (Santa Cruz) was used as a negative control.
Western blotting. Frozen graft neointima from grafts exposed to 4 days of high or normal shear stress were pulverized and extracted with 20 mM Tris, 100 mM sodium chloride, 1 mM EDTA, 0.5% IGEPAL CA-630 (Sigma, St. Louis, Mo), 0.1 mM AEBSF (Calbiochem, San Diego, Calif), pH 8.0. After centrifugation, the concentration of protein in the supernatant was determined (BCA, Pierce, Rockford, Ill), and 30-g samples of protein were subjected to 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by Western blotting. Blots for BMP4 were blocked with 20% normal sheep serum plus 5% albumin for 1 hour at 37°C. Blots were then incubated overnight at 4°C with monoclonal anti-BMP4 at 0.5 g/mL (R & D Systems, Minneapolis, Minn). Protein was visualized by enhanced chemiluminescence (ECL, Amersham Pharmacia, Piscataway, NJ).
In situ hybridization. The BMP4 cDNA clone used for RT-PCR was linearized, transcribed into antisense and sense riboprobes, and labeled with 35 S-UTP (Riboprobe Combination System-SP6/T7 RNA Polymerase, Promega, Madison, Wisc) for in situ hybridization on formalin-fixed sections as described.
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Cell proliferation. Baboon aortic and graft neointimal SMCs grown from explants were cultured in Dulbecco's Modified Eagle Medium with 10% or 20% fetal bovine serum (aortic and neointimal SMCs, respectively). After wiping away endothelial cells, the neointima separates easily and cleanly from the PTFE graft material by dissection. The neointimal SMCs were obtained from the neointimal tissue by outgrowth from about 1-mm 2 explants in which Ͼ99% of neointimal cells are SMCs (by ␣-SM actin immunohistochemical staining; Ͻ0.05% macrophages by HAM56). 8, 18 Essentially 100% of the cultured cells are also ␣-SM actin positive. 19 Subconfluent SMCs were changed to serum-free medium for 72 hours before the addition of recombinant BMP2, BMP4, BMP5, noggin, PDGF-BB 20 (all from R & D Systems), or serum. After 10 hours, 3 H-thymidine (1 Ci/mL) was added. After 28 hours, DNA was harvested and radioactivity was determined as described.
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Cell death. Cell death was determined by detection of cytoplasmic histone/DNA complexes (mono-and oligonucleosomes) by enzyme-linked immunoabsorbent assay (Cell Death Detection kit, Roche Diagnostics, Indianapolis, Ind) following the manufacturer's instructions.
Statistical analysis. Values reported are the mean Ϯ SEM. Each in vitro experiment was repeated at least three times. Statistical significance of DNA synthesis and cell death assays was determined by using multiple analyses of variance and the Student's t test (SPSS Inc, Chicago, Ill).
RESULTS
By 2 months, PTFE grafts develop a thick neointima. 5 We confirmed and extended previous observations 8 that the switch to high flow causes a significant decrease in intimal cross-sectional area by showing that high shear stress increased SMC death and decreased SMC proliferation as early as one day after the switch to high flow (Table I) .
BMP and noggin expression. Because microarray results suggested that members of the BMP family are regulated by high blood flow* we performed Taqman RT-PCR analysis to determine message levels for BMP2, 4, and 5. We found that BMP2 message was increased at days 1 and 7, BMP4 * See supplemental data for a complete description of the microarray experiment. The complete set of array data is at http://www.cs. washington.edu/homes/ruzzo/papers/ATVB/Flow (user: Hsieh; password: ilikethispaper). message was increased on days 4 to 7, and BMP5 message was decreased on day 4 and increased on day 7 (Table II) . In contrast, message levels of noggin, an inhibitor of BMPs, were decreased by high blood flow (Table II) . BMPs inhibit SMC proliferation and increase SMC death. Because BMP2, 4, and 5 were regulated by high blood flow, we investigated the relative activity of each in cultured SMCs. Although each of these BMPs showed a similar inhibitory trend toward PDGF-BBmediated DNA synthesis by baboon aortic SMCs, only BMP4 had a strong, statistically significant effect (about 60% inhibition) (Fig 1, A ) . The BMPs alone had no effect on DNA synthesis (data not presented). BMP4 was the most potent, and no additive effects resulted when BMPs were added in combinations of two (each at 30 ng/mL; data not presented); therefore, the effects of BMP4 were further explored by using baboon PTFE graft neointimal SMCs. As with the aortic SMCs, BMP4 dose-dependently attenuated intimal SMC proliferation in response to PDGF-BB (Fig 1, B) . In both cases the optimal concentration of BMP4 was 30 ng/mL, with higher doses having less effect in a biphasic manner similar to that observed with BMP2.
22 BMP4 also inhibited proliferation of neointimal SMCs mediated by basic fibroblast growth factor (10 ng/ mL) and by 1% fetal bovine serum (data not shown). Noggin alone at 300 ng/mL had no effect on intimal SMC proliferation, but reversed the antiproliferative effect of 30 ng/mL BMP4 by 76% Ϯ 6% (Fig 1, C) . Similar results with noggin were obtained using aortic SMCs (data not presented).
BMP4 alone increased neointimal SMC death by twofold and had more of an effect in the presence of 10ng/mL PDGF-BB or 0.5% serum (Fig 2, A) . Of interest, this effect was only seen after 2 days of treatment (Fig 2, B) . Noggin at 300 ng/mL had no effect on intimal SMC death but reversed the death-inducing effect of BMP4 (30 ng/mL) by 65% Ϯ 5% (P Ͻ .01, n ϭ 3).
BMP4 and BMP receptors in vivo. Levels of BMP4 protein in neointimal extracts as determined by Western blotting were found to be increased twofold by high flow (Fig 3) , which is consistent with the change in mRNA (Table II) . BMP4 mRNA was observed only in endothelial cells by in situ hybridization (Fig 4) . Because BMP4 binds to BMPR-IA, -IB, and -II, 23, 24 we surveyed neointimal expression of these receptors by using immunohistochemistry. Endothelial cells and SMCs in the superficial neointima were positive for BMPR-IA, but SMCs of the deep neointima demonstrated the strongest staining for BMPR-IA, -IB, and -II (Fig 5) . Immunostaining for BMPR-IA, -IB, and -II was not appreciably affected by increased flow (data not shown).
DISCUSSION
In this report, we provide evidence that increased BMP expression, including BMP4, may underlie the neointimal atrophy induced by elevated SS in baboon PTFE grafts. Both SMC proliferation and death are altered by day 1 and message levels of BMP2 are increased by day 1. Although BMP4 RNA is not increased on day 1, message levels of the BMP4 inhibitor, noggin, 25 are decreased by day 1. Loss of the inhibitor raises the possibility that BMP activity is increased before BMP4 protein changes by day 4. BMP2 and BMP7 have been shown to inhibit SMC or mesangial cell proliferation in vitro (and in vivo for BMP2) mediated by PDGF-BB and 1% serum. 22, [26] [27] [28] [29] [30] [31] Although BMP2, 4, and 7 can inhibit SMC growth, this is not universally observed. Takeda et al 27 found that BMPs 2 and 7, but not 4 or 6, inhibited human SMC entry into S phase in response to 1% serum plus PDGF. Nakaoka et al 22 found that BMP2, but not BMP7, inhibited entry into S phase by rat SMCs in response to 10% serum, possibly owing to differential binding to BMP receptors. 32 These BMPs can have other differential effects. For example, BMP2 inhibits, while BMP4 stimulates, expression of the SMC markers ␣-SM22 and ␣-smooth muscle actin. 32, 33 The observation that BMP4 had similar effects on aortic and graft SMCs is important, because graft SMCs are primarily derived from pericytes and Yang et al 34 found opposite effects of BMP4 on the growth of SMCs from different vascular beds.
BMPs are members of the transforming growth factor (TGF)-␤ superfamily. They regulate cell proliferation, differentiation, migration, and apoptosis during embryonic development. 25, [35] [36] [37] BMPs are dimers that bind two type I (BMPRIA and -IB, or ActR-I) and one type II (BMPR-II or ActR-IIB) serine/threonine kinase receptors. 37 Noggin is one of a number of secreted BMP antagonists that acts by binding BMPs and preventing their interaction with BMP receptors. 25, 38 Binding of BMP to the BMPRs leads to phosphorylation of the type I receptor by the type II receptor. In turn the type I receptor phosphorylates Smads (intracellular mediators), which then move to the nucleus and act in concert with other molecules to regulate transcription. 37 Evidence has also accumulated indicating that BMPs can activate members of the mitogen-activated protein kinase (MAPK) pathways. There are reports of both cooperative and antagonistic interactions between the p38 and Smad pathways. [39] [40] [41] BMPs probably play an important role in vascular disease. Genetic defects of BMP receptors (BMPRs) have been linked to the pathogenesis of pulmonary artery hypertrophy and hypertension in humans. 42, 43 . In addition, BMP2 and BMP4 have been detected in atherosclerotic plaques. 44 Although hemodynamic forces, especially shear stress, have been shown to regulate gene expression in arteries and vascular implants 45, 46 via specific 5= shear response elements, [47] [48] [49] there are no known shear response elements in the 5= promoter region of BMP2 or BMP4. The delayed induction of BMP4 in vivo suggests that intermediate factors control BMP4 expression. Sorescu et al 50 reported that increasing levels of laminar shear decreased BMP4 expression in endothelial cells in Յ24 hours. In addition, laminar shear stress increased Smad6 and -7 transcription in Յ3 hours. 51 How these in vitro data relate to the in vivo hemodynamic environment is not clear. In contrast to BMP4, the 5= upstream region of noggin contains a consensus sequence for AP-1 that is required for shear stressmediated downregulation of vascular cell adhesion molecule-1 in endothelial cells. 52, 53 Thus, AP-1 may mediate the downregulation of noggin observed after the switch to high shear stress.
The mechanisms by which BMP4 inhibits SMC proliferation and causes cell death are not known. BMP2 increases levels of the cell cycle inhibitor, p21, and antisensemediated reduction of p21 blocks the inhibitory effect of BMP2 on aortic SMC proliferation. 29 Wong et al 29 found that 1 day of treatment with BMP2 did not cause SMC death, but Zhang et al 54 observed substantial apoptosis in pulmonary SMCs after two days of treatment with either BMP2 or BMP7. These investigators found that BMP2 increased Smad1 phosphorylation by 2 hours and decreased levels of the antiapoptotic protein, Bcl2, by 24 hours.
In contrast to Zhang et al, Dorai et al 26 reported that BMP7 inhibited aortic SMC death (in data not shown), which they ascribed to the loss of p53. We also found that longer times were required for the apoptosis inducing effect of BMP4 in the baboon graft intimal SMCs. This suggests a dependence of the process on the synthesis of upstream proapoptotic mediators or slow turnover of antiapoptotic factors. Alternatively, BMP4 may cause SMCs to become dependent on exogenous survival factors. 55 In other in vitro cell systems, death caused by BMP4 and BMP2 is mediated by Smad1/5 and p38 MAPK 56, 57 induction of the transcriptional regulator Msx2 57, 58 and repression of the anti-apoptotic protein Bcl-Xs. 57 Of particular interest is the observation that specific cell-cell and cell matrix interactions are required for the effect of BMP4 and Msx2 expression on cell death. 58 In this regard, SMC death is only observed in the deep neointima, which has more (and more tightly organized) collagen I and biglycan with less glycosaminoglycans compared with the subendothelial matrix. 9 This difference in matrix may alter both the effect and distribution of BMP4. Heparan sulfate proteoglycans such as the glypicans may regulate the distribution and activity of BMP4 and noggin. 59 ,60
CONCLUSION
The counter-regulation of BMP4 and noggin coupled with the growth inhibitory and proapoptotic effects of BMP4 in vitro support a role for BMP4 and noggin in shear stress-mediated neointimal atrophy. These data plus the data linking BMPR mutations to pulmonary hypertension 42, 43 and showing the increased presence of BMPs in atherosclerotic lesions 44 suggest that BMPs play a significant role in vascular pathology. Understanding the function and regulation of BMP ligands, BMPRs, antagonists (eg, noggin) and, in particular, the signaling mechanisms of BMP4 in controlling SMC proliferation and death may lead to therapeutic tools for the prevention or reversal of neointimal hyperplasia.
